What Will Fuel M&A Fire In 2025, Will PE Firms Star In Biggest Deals In India Again?

CRDMOs In Focus Amid China Decoupling

PE firms Advent and Carlyle drove the biggest M&A deals in human and animal pharmaceuticals in India during 2024, a year that also saw Lupin strike deals with Eli Lilly and Boehringer Ingelheim to further its ambitions in the fast-growing diabetes space. Which segments look hot and what are the expected trends for deal making in 2025?

Looking out for M&A deals
What's On The India M&A Deal Horizon In 2025? (Shutterstock)

Mankind Pharma Ltd’s acquisition of Bharat Serums and Vaccines Ltd (BSV) for INR136.3bn ($1.6bn) was without doubt the showstopper in 2024. As private equity (PE) firm Advent profitably exited BSV, the deal left Mankind seeking INR100bn in funds for the global toehold, R&D platform and niche therapy strength offered by the acquired company.

More from Scrip Perspectives

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

M&A Takeoff May Be Delayed, Experts Predict

 

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.

10 Clinical Trials To Look Out For In 2025

 

Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.

More from Deals

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By 

South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.

Novo Gets Its Own ‘Triple G’ Obesity Drug To Rival Lilly

 

The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.

AstraZeneca Expands Emphasis On China, Already A Key Market

 
• By 

UK pharma will invest $2.5bn in Beijing R&D hub, build a vaccine manufacturing site with BioKangtai, and partner in chronic disease with Syneron and in oncology/immunology with Harbour BioMed.